Research Analysts Issue Forecasts for Amarin Co. plc’s Q1 2018 Earnings (AMRN)

Amarin Co. plc (NASDAQ:AMRN) – Equities research analysts at SunTrust Banks issued their Q1 2018 EPS estimates for shares of Amarin in a report issued on Thursday. SunTrust Banks analyst J. Boris forecasts that the biopharmaceutical company will post earnings of ($0.07) per share for the quarter. SunTrust Banks also issued estimates for Amarin’s Q2 2018 earnings at ($0.05) EPS, Q3 2018 earnings at ($0.05) EPS and Q4 2018 earnings at ($0.03) EPS.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. The firm’s quarterly revenue was up 45.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.08) earnings per share.

AMRN has been the subject of a number of other reports. Cantor Fitzgerald set a $10.00 price objective on shares of Amarin and gave the company a “buy” rating in a report on Wednesday, December 6th. ValuEngine raised shares of Amarin from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. BidaskClub raised shares of Amarin from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Jefferies Group reissued a “buy” rating on shares of Amarin in a research report on Wednesday, October 11th. Finally, Zacks Investment Research lowered shares of Amarin from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $7.75.

Shares of Amarin (NASDAQ:AMRN) traded up $0.02 during midday trading on Monday, hitting $4.30. 983,300 shares of the stock were exchanged, compared to its average volume of 1,416,567. The firm has a market capitalization of $1,150.00, a PE ratio of -15.93 and a beta of 0.62. Amarin has a 52-week low of $2.81 and a 52-week high of $4.47. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.32.

In related news, insider Steven B. Ketchum sold 128,257 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $4.25, for a total transaction of $545,092.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Steven B. Ketchum sold 64,683 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $4.40, for a total transaction of $284,605.20. The disclosure for this sale can be found here. 3.72% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the business. Westside Investment Management Inc. raised its position in Amarin by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 300 shares during the period. Wells Fargo & Company MN raised its position in Amarin by 15.2% in the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 5,000 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Amarin in the third quarter worth about $226,000. Stevens Capital Management LP bought a new stake in Amarin in the third quarter worth about $229,000. Finally, Stonepine Capital Management LLC bought a new stake in Amarin in the second quarter worth about $302,000. 40.12% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2018/01/10/research-analysts-issue-forecasts-for-amarin-co-plcs-q1-2018-earnings-amrn.html.

About Amarin

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit